Deborah Dunsire after three years at Lundbeck: "We're coming up to an inflection point in neuroscience"

Before she took on the role, Deborah Dunsire knew perfectly well that drug development within neurology and psychiatry comes with its own unique challenges compared to cancer, an area in which she has spent the majority of her career. Improvements for brain disorders are on the way, but the road ahead is long, says the CEO at Lundbeck.
Photo: Gregers Tycho/ERH
Photo: Gregers Tycho/ERH
by ELIZABETH MØNSTED JOHANSEN, translated by Daniel Pedersen

In many ways, it was a journey back in time for Deborah Dunsire when she took the job as CEO at Lundbeck. This is not to say Denmark's life sciences industry is lagging behind the US. Rather, it has something to do specifically with the disease area with which she is now working.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading